|
SELECT (the Selenium and Vitamin E Cancer Prevention Trial) is the largest prostate cancer prevention trial ever conducted. Previous studies suggest that selenium and vitamin E (alone or in combination) may reduce the risk of developing prostate cancer by 60 percent and 30 percent, respectively, but only a large clinical trial such as SELECT can confirm those initial findings.
SELECT began enrolling patients on August 22, 2001, and closed enrollment on June 24, 2004, with 35,534 participants; about 15 percent of those participants are African-American. The Department of Preventive Medicine recruited 401 participants for the SELECT study; about 48 percent of those participants are African-American.
The study includes men 55 and older. African-American men 50 and over were eligible to enroll because prostate cancer strikes African-American men earlier and more often than white men. There are 435 SELECT sites throughout the United States, Puerto Rico and Canada.
Coordinated by a network of researchers called the Southwest Oncology Group (SWOG), the study is sponsored by the National Cancer Institute (NCI).
Principal Site Investigator
Steven K. Rothschild, MD
Head Clinical Research Associate
Rolanda J. Flynn
Rolanda_J_Flynn@rush.edu
(312) 563-2242
|
